These Analysts Slash Their Forecasts On Century Therapeutics After Weak Q2 Results
Century Therapeutics, Inc. (NASDAQ: IPSC) reported weaker-than-expected second-quarter results.
Century Therapeutics: Q1 Earnings Insights
Century Therapeutics (NASDAQ:IPSC) reported its Q1 earnings results on Thursday, May 11, 2023 at 07:30 AM. Here’s what…
Century Therapeutics Announces Leadership Changes; Lalo Flores, Steps Down As CEO And Member Of Board Of Directors; Greg Russotti, Chief Technology Officer, Assumes Role Of Ad-Interim CEO; Michael C. Diem, Promoted To CFO
– Lalo Flores, Ph.D., steps down as Chief Executive Officer and member of Board of Directors; Greg Russotti, Ph.D., Chief Technology Officer, assumes role of ad-interim Chief Executive Officer
Where Century Therapeutics Stands With Analysts
Century Therapeutics (NASDAQ:IPSC) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…
8 Analysts Have This to Say About Century Therapeutics
Within the last quarter, Century Therapeutics (NASDAQ:IPSC) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…
SVB Leerink Maintains Outperform on Century Therapeutics, Lowers Price Target to $14
SVB Leerink analyst Daina Graybosch maintains Century Therapeutics (NASDAQ:IPSC) with a Outperform and lowers the price target from $20 to $14.